An Expanding Chemogenomic Toolbox Gives Kinome Research a Welcome and Much Needed Boost
The human kinome includes 500+ druggable targets, with 35+ small molecule kinase inhibitors approved by the FDA since 2000. Remarkable. Despite the... Read More
Webinar Recap: Unlocking GPCR’s for Oncology
Surprisingly few GPCR-targeted therapies have been developed for oncology, despite frequent disregulation of the receptors and their signaling mediators that control pro-survival... Read More
Kinome-wide Profiling of Existing Chemical Assets: A Powerful Strategy to Jump-start New Drug Discovery Programs
Kinase inhibitors are among the fastest growing classes of FDA-approved drugs, and it has been satisfying to see that three have now... Read More